|
We are a specialty healthcare product company focused on developing and commercializing innovative treatments for underserved patient populations. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either bringing the technologies to market or out-licensing.
In the short term we are focusing our efforts on the commercialization of the two product candidates we currently have in development:
Hedrin™, a novel, non-insecticide treatment for pediculosis (head lice)
Topical GEL for the treatment of psoriasis
Longer term, we intend to acquire and commercialize low risk, quick to market products, specifically products that could be marketed over-the-counter ("OTC"), treat everyday maladies, are simple to manufacture, and/or could be classified as medical devices by the FDA.
| Copyright © Manhattan Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy. |